Bennett, Jeffrey L.

International consensus diagnostic criteria for neuromyelitis optica spectrum disorders

Wingerchuk, D. M., Banwell, B., Bennett, J. L., Cabre, P., Carroll, W., Chitnis, T., de Seze, J., Fujihara, K., Greenberg, B., Jacob, A., et al. (2015) · Neurology

Multiple Sclerosis Research StudiesPeripheral Neuropathies and Disorders

Cited by 4,649

A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking

Teunissen, C. E., Petzold, A., Bennett, J. L., Berven, F. S., Brundin, L., Comabella, M., Franciotta, D., Frederiksen, J. L., Fleming, J. O., Furlan, R., et al. (2009) · Neurology

Clinical Laboratory Practices and Quality ControlMultiple Sclerosis Research Studies

Cited by 845

Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial

Cree, B. A. C., Bennett, J. L., Kim, H. J., Weinshenker, B. G., Pittock, S. J., Wingerchuk, D. M., Fujihara, K., Paul, F., Cutter, G. R., Marignier, R., et al. (2019) · The Lancet

Multiple Sclerosis Research StudiesPeripheral Neuropathies and Disorders

Cited by 756

MRI characteristics of neuromyelitis optica spectrum disorder: An international update

Kim, H. J., Paul, F., Lana-Peixoto, M. A., Tenembaum, S., Asgari, N., Palace, J., Klawiter, E. C., Sato, D. K., de Seze, J., Wuerfel, J., et al. (2015) · Neurology

Multiple Sclerosis Research StudiesPeripheral Neuropathies and Disorders

Cited by 664

Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial

Traboulsee, A., Greenberg, B. M., Bennett, J. L., Szczechowski, L., Fox, E., Shkrobot, S., Yamamura, T., Terada, Y., Kawata, Y., Wright, P., et al. (2020) · The Lancet Neurology

Multiple Sclerosis Research StudiesPeripheral Neuropathies and Disorders

Cited by 513

Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial

Zhang, C., Zhang, M., Qiu, W., Ma, H., Zhang, X., Zhu, Z., Yang, C.-S., Jia, D., Zhang, T.-X., Yuan, M., et al. (2020) · The Lancet Neurology

Multiple Sclerosis Research StudiesPeripheral Neuropathies and Disorders

Cited by 287

Treatment of neuromyelitis optica: state-of-the-art and emerging therapies

Papadopoulos, M. C., Bennett, J. L., & Verkman, A. S. (2014) · Nature Reviews Neurology

Multiple Sclerosis Research StudiesPeripheral Neuropathies and Disorders

Cited by 262

Impairment of mitochondrial transcription termination by a point mutation associated with the MELAS subgroup of mitochondrial encephalomyopathies

Hess, J. F., Parisi, M. A., Bennett, J. L., & Clayton, D. A. (1991) · Nature

Mitochondrial Function and PathologyRNA and protein synthesis mechanisms

Cited by 234

Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment

Bennett, J. L., Costello, F., Chen, J. J., Petzold, A., Biousse, V., Newman, N. J., & Galetta, S. L. (2023) · The Lancet Neurology

Multiple Sclerosis Research StudiesOcular Diseases and Behçet’s Syndrome

Cited by 226

Loss of Myelin Basic Protein Function Triggers Myelin Breakdown in Models of Demyelinating Diseases

Weil, M.-T., Möbius, W., Winkler, A., Ruhwedel, T., Wrzos, C., Romanelli, E., Bennett, J. L., Enz, L., Goebels, N., Nave, K.-A., et al. (2016) · Cell Reports

Multiple Sclerosis Research StudiesPeripheral Neuropathies and Disorders

Cited by 142

Pharmacological Properties, Toxicology and Scientific Rationale for the use of Natalizumab (Tysabri®) in Inflammatory Diseases

Stüve, O., & Bennett, J. L. (2007) · CNS Drug Reviews

Multiple Sclerosis Research StudiesCell Adhesion Molecules Research

Cited by 123

Concentration-dependent effects of CSF1R inhibitors on oligodendrocyte progenitor cells ex vivo and in vivo

Liu, Y., Given, K. S., Dickson, E. L., Owens, G. P., Macklin, W. B., & Bennett, J. L. (2019) · Experimental Neurology

Neurogenesis and neuroplasticity mechanismsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 105

Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD

Yan, Y., Li, Y., Fu, Y., Yang, L., Su, L., Shi, K., Li, M., Liu, Q., Borazanci, A., Liu, Y., et al. (2016) · Science China Life Sciences

Multiple Sclerosis Research StudiesAutoimmune Neurological Disorders and Treatments

Cited by 63

Deletional tolerance prevents AQP4‐directed autoimmunity in mice

Vogel, A., Knier, B., Lammens, K., Kalluri, S. R., Kuhlmann, T., Bennett, J. L., & Korn, T. (2017) · European Journal of Immunology

Multiple Sclerosis Research StudiesT-cell and B-cell Immunology

Cited by 34

Variable sensitivity to complement-dependent cytotoxicity in murine models of neuromyelitis optica

Liu, Y., Harlow, D. E., Given, K. S., Owens, G. P., Macklin, W. B., & Bennett, J. L. (2016) · Journal of Neuroinflammation

Multiple Sclerosis Research StudiesComplement system in diseases

Cited by 17

Structural basis of aquaporin-4 autoantibody binding in neuromyelitis optica

Gupta, M., Khandelwal, N. K., Nelson, A., Hwang, P., Pourmal, S., Bennett, J. L., & Stroud, R. M. (2025) · Science Advances

Ion Transport and Channel RegulationMultiple Sclerosis Research Studies

Cited by 11

Establishing demographic-based normative values for neurofilament light chain and glial fibrillary acidic protein in serum and plasma samples

Borko, T. L., Ritchie, A., Selva, S., Sillau, S., Engebretson, E., Wolf, A. B., Alvarez, E., Gross, R., Gutierrez, E., Corboy, J., et al. (2026) · Multiple Sclerosis Journal – Experimental, Translational and Clinical

Clinical Laboratory Practices and Quality ControlMultiple Sclerosis Research Studies

Cited by 1